Middle East Cancer Treatment Market Research Report, Analysis and Forecast

Middle East Cancer Treatment Market Synopsis

Cancer treatment has become a critical area of focus in the Middle East, as the region experiences a growing incidence of cancer cases. A range of innovative and highly effective cancer treatments, including Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, are in high demand to provide the best possible care for cancer patients. The availability of these treatments has helped to increase the survival rates of patients suffering from various types of cancer, including blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others.

The increasing demand for these cancer treatments is driven by factors such as the ageing population, growing awareness of cancer risk factors, and improved access to medical care in the Middle East. Additionally, the Middle East has seen a growth in the availability of cancer specialists and a rise in the number of cutting-edge medical facilities, which has further fueled the demand for advanced cancer treatments in the region.

According to the World Health Organization, cancer is the second leading cause of death in the Middle East.
The most common types of cancer in the Middle East are breast, colorectal, and lung cancer.
In the Middle East, only about 10% of cancer patients receive treatment due to a lack of access to healthcare and financial resources
In recent years, there has been an increase in the use of targeted therapies and immunotherapies for cancer treatment in the Middle East.

The rise in demand for cancer treatments in the Middle East is presenting significant business opportunities for pharmaceutical and biotechnology companies, as well as healthcare providers. This growing market is expected to continue to offer significant potential for growth, as the region’s population continues to increase and the need for advanced cancer treatments remains high.

Middle East Cancer Treatment Market: Overview

Cancer treatment refers to the various medical and therapeutic methods used to treat cancer, a disease characterized by the uncontrolled growth and spread of abnormal cells. Some of the most common forms of cancer include blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. The type of cancer treatment recommended depends on various factors such as the type and stage of cancer, the patient’s overall health, and the goals of treatment, which can range from curing cancer to reducing symptoms and improving quality of life. Some of the most common cancer treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy.

Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar have commonly used drugs for cancer treatment. These drugs are used to treat various types of cancers, such as blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. The choice of drugs and the specific treatment regimen will depend on the type and stage of cancer, as well as the patient’s overall health and other factors.

Revlimid is a medication used in the treatment of blood cancers, such as multiple myeloma.

Avastin is a medication used in the treatment of a variety of cancers, including colorectal, lung, and brain cancer.
Herceptin is a medication used in the treatment of breast cancer, specifically HER2-positive breast cancer.
Rituxan is a medication used in the treatment of blood cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia.
Opdivo is a medication used in the treatment of a variety of cancers, including lung, bladder, and skin cancer.
Gleevec is a medication used in the treatment of chronic myeloid leukaemia and some types of gastrointestinal stromal tumours.

Saudi Arabia Cancer Treatment Market Synopsis

Saudi Arabia’s cancer treatment market is also growing rapidly due to its high prevalence of cancer. The country has one of the highest rates of cancer in the world, with an estimated 10,000 new cases reported each year. As a result, there is a growing demand for advanced treatments and technologies such as radiotherapy, chemotherapy, and immunotherapy. Additionally, Saudi Arabia’s government has invested heavily in healthcare infrastructure and research to improve access to quality cancer care. This has increased the number of specialized cancer centres and hospitals offering advanced treatments for various types of cancers.

UAE Cancer Treatment Market Synopsis

The UAE cancer treatment market is growing rapidly due to the increasing prevalence of cancer in the region. The UAE has one of the highest rates of cancer in the world, with an estimated 5,000 new cases reported each year. This has led to a surge in demand for advanced cancer treatments and technologies, such as radiotherapy, chemotherapy, and immunotherapy. Additionally, the UAE government has invested heavily in healthcare infrastructure and research to improve access to quality cancer care. This has increased the number of specialized cancer centres and hospitals offering advanced treatments for various types of cancers.

Middle East Cancer Treatment Market: Segmentation

The middle east Cancer Treatment market has been segmented into Application and Top Selling Drugs.

Based on the application, the middle east Cancer Treatment market is segmented into Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, and Others. In 2021, Lung Cancer held a significant revenue share. This is because of the increased prevalence of smoking and air pollution, which are the two main causes of lung cancer. Additionally, the development of more advanced diagnostic techniques and treatments has also led to an increase in the number of lung cancer cases. As a result, the demand for cancer treatment and preventive measures is likely to grow, leading to further investments in this field. For instance, advances in artificial intelligence and machine learning have enabled the development of early diagnostic tools, which have greatly improved the accuracy of lung cancer detection.

Based on Top Selling Drugs, the market is classified as Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others. In 2021, the Revlimid segment is expected to dominate the market share. This is due to its increasing use in the treatment of multiple myeloma and other hematologic malignancies. It is also expected to have a significant impact on the market due to its high efficacy and safety. Furthermore, the availability of generic Revlimid is likely to further drive up its market share and make it an increasingly attractive therapeutic option. For instance, generic versions of Revlimid have been approved in the United States and Europe, leading to a decrease in the cost of the drug and an increase in its market share.

Recent Developments

In 2021, the Middle East cancer treatment space saw many significant developments.
In June 2021, Dubai-based Aster DM Healthcare announced its acquisition of Saudi Arabia’s National Guard Health Affairs (NGHA). The acquisition will give Aster access to NGHA’s network of hospitals and clinics across Saudi Arabia, as well as its advanced cancer treatment capabilities.
In January, the UAE-based healthcare provider NMC Healthcare announced its merger with Al Zahra Hospital Sharjah to create a new entity called NMC Healthcare Sharjah. The merger is expected to expand NMC’s presence in the region and provide access to advanced cancer treatments for patients in the UAE.
In February, Saudi Arabia-based King Faisal Specialist Hospital and Research Centre (KFSH&RC) launched a new cancer treatment centre in Riyadh. The centre is equipped with advanced technology and offers comprehensive cancer care services including chemotherapy, radiation therapy, surgery, and immunotherapy.
In March, Dubai-based Aster DM Healthcare opened its first dedicated cancer care centre in Dubai. The centre offers comprehensive cancer care services including chemotherapy, radiation therapy, surgery, and immunotherapy.
In April, Saudi Arabia-based National Cancer Institute (NCI) opened its first branch in Riyadh. The institute provides advanced treatments for various types of cancers including breast cancer, colorectal cancer, lung cancer and prostate cancer.
In May, Qatar-based Hamad Medical Corporation (HMC) launched a new oncology centre at Al Wakra Hospital in Doha. The centre is equipped with advanced technology and offers comprehensive cancer care services including chemotherapy, radiation therapy, surgery and immunotherapy.
These developments demonstrate the commitment of healthcare providers in the Middle East to providing access to advanced treatments for patients suffering from various types of cancers.

In 2022, there were several acquisitions in the Middle East Cancer Treatment company space.

In April 2022, Al Borg Medical Laboratories acquires Oncology Care Egypt in Saudi Arabia.
In May 2022, Abraaj Group acquires a majority stake in National Cancer Care Company in Saudi Arabia.
In June 2022, Mubadala Investment Company acquires a majority stake in UAE’s National Cancer Care Company.
In July 2022, Al Rayan Investment Group acquires a majority stake in Qatar Cancer Treatment Center.
In August 2022, Investcorp acquires a majority stake in Bahrain Cancer Treatment Center.

These acquisitions reflect the increasing significance of cancer treatment companies in the Middle East and the potential for further growth and consolidation in the sector.